Cargando…

Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis

INTRODUCTION: Chemotherapy-induced peripheral neuropathy (CIPN) can lead to chemotherapy dose reduction, delay, and discontinuation, and has limited effective prevention strategies. Our study aimed to identify patient characteristics associated with CIPN severity during weekly paclitaxel chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhi, Wanqing Iris, Dreyfus, Nechama, Lessing, Alexie, Galantino, Marylou, Piulson, Lauren, Kot, Kevin Liu, Li, Susan, Bao, Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Breast Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322124/ https://www.ncbi.nlm.nih.gov/pubmed/36972359 http://dx.doi.org/10.1093/oncolo/oyad062

Ejemplares similares

Yoga for cancer survivors with chemotherapy‐induced peripheral neuropathy: Health‐related quality of life outcomes
por: Zhi, W. Iris, et al.
Publicado: (2021)

Yoga for Chemotherapy-Induced Peripheral Neuropathy and Fall Risk: A Randomized Controlled Trial
por: Bao, Ting, et al.
Publicado: (2020)

Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain
por: Zhi, W. Iris, et al.
Publicado: (2018)

Effect of Acupuncture vs Sham Procedure on Chemotherapy-Induced Peripheral Neuropathy Symptoms: A Randomized Clinical Trial
por: Bao, Ting, et al.
Publicado: (2020)

Clinical outcomes and prognostic factors in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy followed by surgery and postmastectomy radiation therapy in the modern treatment era
por: Nakajima, Naomi, et al.
Publicado: (2018)

A Phase II Trial of Cabozantinib in Hormone Receptor‐Positive Breast Cancer with Bone Metastases
por: Xu, Jing, et al.
Publicado: (2020)

Effects of Exercise on Chemotherapy Completion and Hospitalization Rates: The OptiTrain Breast Cancer Trial
por: Mijwel, Sara, et al.
Publicado: (2019)

Comparative Effectiveness of Palliative Chemotherapy in Metastatic Breast Cancer: A Real‐World Evidence Analysis
por: Feinberg, Bruce, et al.
Publicado: (2020)

Duration of Chemotherapy-induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles
por: Navari, Rudolph, et al.
Publicado: (2022)

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Vernaci, Grazia, et al.
Publicado: (2023)

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
por: Litton, Jennifer K, et al.
Publicado: (2023)

Outcomes of Breast Cancer Patients Treated with Chemotherapy, Biologic Therapy, Endocrine Therapy, or Active Surveillance During the COVID-19 Pandemic
por: Marks, Douglas K, et al.
Publicado: (2022)

CT Radiomics for Predicting Pathological Complete Response of Axillary Lymph Nodes in Breast Cancer After Neoadjuvant Chemotherapy: A Prospective Study
por: Li, Yan-Ling, et al.
Publicado: (2023)

Regional Recurrence Rates With or Without Complete Axillary Dissection for Breast Cancer Patients with Node-Positive Disease on Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy
por: Ling, Diane C., et al.
Publicado: (2019)

A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial
por: Blackwell, Kimberly, et al.
Publicado: (2016)

Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2020)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]‐Fluorothymidine Positron Emission Tomography Biomarker Study
por: Wesolowski, Robert, et al.
Publicado: (2020)

Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan
por: Bardia, Aditya, et al.
Publicado: (2022)

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
por: Hurvitz, Sara A., et al.
Publicado: (2019)

Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor‐Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care‐BC): A Randomized Controlled Phase III Trial
por: Niikura, Naoki, et al.
Publicado: (2019)

Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer
por: Ge, Xuan, et al.
Publicado: (2023)

Cardiac-sparing radiation therapy using positioning breast shell for patients with left-sided breast cancer who are ineligible for breath-hold techniques
por: Joseph, Kurian, et al.
Publicado: (2017)

Breast Cancer and Pregnancy: Current Concepts in Diagnosis and Treatment
por: Litton, Jennifer K., et al.
Publicado: (2010)

Underuse of Anthracyclines in Women with HER-2(+) Advanced Breast Cancer
por: Montemurro, Filippo, et al.
Publicado: (2010)

Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis
por: Niikura, Naoki, et al.
Publicado: (2011)

A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience
por: McKee, Megan J., et al.
Publicado: (2016)

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer
por: Kadakia, Kunal C., et al.
Publicado: (2016)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Tamoxifen Initiation After Ductal Carcinoma In Situ
por: Nichols, Hazel B., et al.
Publicado: (2016)

Pentoxifylline and vitamin E drug compliance after adjuvant breast radiation therapy
por: Famoso, Justin M., et al.
Publicado: (2017)

Predictors of radiation-induced acute skin toxicity in breast cancer at a single institution: Role of fractionation and treatment volume
por: Parekh, Arti, et al.
Publicado: (2017)

Lymphangioleiomyomatosis: A new relative contraindication for breast conservation therapy
por: Mallory, Matthew L., et al.
Publicado: (2017)

Adipose‐Derived Fatty Acid‐Binding Proteins Plasma Concentrations Are Increased in Breast Cancer Patients
por: Guaita‐Esteruelas, Sandra, et al.
Publicado: (2017)

Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case‐Control Study in Northern and Eastern China and Implications for Chemoprevention
por: Wang, Fei, et al.
Publicado: (2017)

A component of lobular carcinoma in clinically lymph node–negative patients predicts for an increased likelihood of upstaging to pathologic stage III breast cancer
por: Van Wyhe, Renae D., et al.
Publicado: (2018)

Is completion axillary lymph node dissection necessary in patients who are underrepresented in the ACOSOG Z0011 trial?
por: Gebhardt, Brian J., et al.
Publicado: (2018)

Implementation and utilization of hypofractionation for breast cancer
por: Gilbo, Philip, et al.
Publicado: (2018)

Koebner phenomenon: Consideration when choosing fractionation for breast irradiation
por: Wu, Cheng-Chia, et al.
Publicado: (2017)

Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results
por: Andersson, Michael, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mg2ivqnmdit8g0bhapsesini41